# Smart Inhalers Market

> Smart inhalers market: USD 317.5 million in 2025, growing 15.27% a year to 2035 as RPM billing and new FDA-cleared inhaler sensors widen use.

Publisher: Douglas Insights  
Author: Douglas Insights Research Desk  
Report code: DI-HC-10475  
Published: 2026-10-05  
Last updated: 2026-10-05  
Next review: Apr 2027  
Page: https://www.douglasinsights.com/smart-inhalers-market/

## Key figures

| Measure | Value | How it is built |
| --- | --- | --- |
| Market size · 2025 | $317.5 Mn | 1.372 million device-years x USD 231.4 = USD 317.5 million. |
| Forecast · 2035 | $1,315.1 Mn | USD 1.32 billion in the base case; slower case USD 893.3 million, faster case USD 1.88 billion. |
| Revenue CAGR · 2026-2035 | 15.27% | (1.134 x 1.0165) - 1 = 15.27% a year. |
| Volume · 2035 | 4.825 million device-years | 1.372 million device-years grown 13.4% a year for 10 years. |
| Leading segment | Add-on sensors for pMDIs, 38.7% | USD 122.8 million in 2025; one clip-on fits many canister brands. |
| Fastest segment | Remote monitoring and adherence services, 19.3% | USD 87.0 million in 2025 to USD 508.1 million in 2035, driven by monthly RPM billing. |
| Fastest region | Asia Pacific, 20.6% | USD 45.1 million in 2025 to USD 293.5 million in 2035. |
| Leading region | North America, 51.9% | USD 164.8 million in 2025, reaching USD 627.2 million in 2035. |
| Market leader | ResMed (Propeller Health), about 21.6% | Douglas Insights estimate; top three platforms about 36.2%. |
| Event | FDA 510(k) clearance of Aptar HeroTracker Sense, 16 October 2025 | Class II clip-on for pMDIs including Ventolin HFA and Advair. |

## Key takeaways

- Smart inhalers generate USD 317.5 million in 2025: 1.372 million device-years at USD 231.4 each.
- The base case reaches USD 1.32 billion by 2035, a 15.27% CAGR from 13.4% volume and 1.65% price growth.
- Add-on sensors for pMDIs hold 38.7%, while remote monitoring and adherence services grow fastest at 19.3% a year.
- North America holds 51.9% of 2025 value; Asia Pacific grows fastest at 20.6% a year.
- One point of extra volume growth adds about USD 120.7 million to the 2035 total.

More than 180,000 connected respiratory devices have been sold worldwide by a single sensor maker, according to [Adherium's 10 March 2026 sales update to the Australian Securities Exchange (ASX)](https://announcements.asx.com.au/asxpdf/20260310/pdf/06x7w6273qyj2t.pdf), and that installed base is only one slice of the Smart Inhalers market. Smart inhalers are inhalers fitted with, or built around, a Bluetooth sensor that logs each dose, its timing and often the patient's inhalation technique; the market covers add-on sensors, integrated connected inhalers and the remote monitoring services billed around them, but not the drug inside the device. At 1.372 million device-years in use and a blended USD 231.4 per device-year, 2025 revenue comes to USD 317.5 million. Douglas Insights projects USD 1.32 billion by 2035, a revenue compound annual growth rate (CAGR) of 15.27% built from 13.4% volume growth and 1.65% price growth. The newest regulatory signal arrived on 16 October 2025, when [Aptar Digital Health received Food and Drug Administration (FDA) 510(k) clearance for HeroTracker Sense](https://aptar.com/news-events/aptar-digital-health-announces-fda-510-k-clearance-for-herotracker-sense), a clip-on for pressurised metered dose inhalers (pMDIs). The study is part of our [respiratory care devices](https://www.douglasinsights.com/industry/healthcare/medical-devices/respiratory-care-devices/) coverage and follows the [Douglas Insights research methodology](https://www.douglasinsights.com/research-methodology/).

## Which smart inhaler format makes the money: pMDI clip-ons, DPI sensors or monitoring services?

Add-on sensors for pressurised metered dose inhalers lead the smart inhaler market with 38.7% of 2025 value, or USD 122.8 million, because a clip-on fits canisters patients already use. Remote monitoring and adherence services follow at 27.4% and grow fastest, at 19.3% a year to 2035.

| Smart inhaler segment | Share 2025 | Value 2025 | Growth 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- |
| Add-on sensors for pressurised metered dose inhalers | 38.7% | USD 122.8 million | 14.4% | USD 471.5 million |
| Add-on sensors for dry powder inhalers | 17.6% | USD 55.9 million | 15.7% | USD 240.3 million |
| Integrated connected inhalers | 16.3% | USD 51.8 million | 6.2% | USD 94.5 million |
| Remote monitoring and adherence services | 27.4% | USD 87.0 million | 19.3% | USD 508.1 million |

Add-on sensors for pressurised metered dose inhalers hold USD 122.8 million because one sensor body can be adapted to many canister brands, and they reach USD 471.5 million by 2035 at 14.4% a year. Add-on sensors for dry powder inhalers (DPIs) carry USD 55.9 million, a 17.6% share, held back by the need for a sensor shaped to each device body, as with the sensor Propeller Health custom-built for the Breezhaler. Integrated connected inhalers account for USD 51.8 million, or 16.3%, and grow just 6.2% a year after Teva stopped making its three Digihaler inhalers, removing the best-known built-in range from US pharmacies.

Remote monitoring and adherence services are worth USD 87.0 million in 2025 and are the fastest-growing segment at 19.3% a year. The reason is billing: a clinic earns a monthly fee for reviewing smart inhaler data, while hardware is sold once. Douglas Insights counts asthma at about 71.4% of 2025 device-years and chronic obstructive pulmonary disease (COPD) at 28.6%, because most cleared sensors fit asthma controllers and rescue inhalers first. Readers following nebulisers and spacers will find them in our [Aerosol Therapy Market](https://www.douglasinsights.com/aerosol-therapy-market/).

## Why are allergy clinics and drug makers now paying for smart inhaler adherence data?

Smart inhaler volume grows 13.4% a year to 2035, built from three forces that add device-years. Remote patient monitoring (RPM) billing adds 5.6 points, wider drug compatibility adds 4.3 points and the burden of uncontrolled asthma and COPD adds 3.5 points.

### RPM billing adds 5.6 points

Clinic billing is the largest smart inhaler driver. Adherium's [quarterly report of 29 April 2026](https://announcements.asx.com.au/asxpdf/20260429/pdf/06yzsssz90rd8p.pdf) shows RPM subscription revenue of A$344k in the three months to 31 March 2026, up 101% from A$171k a quarter earlier. Cumulative RPM device shipments reached 3,617 and patient activations 2,622, up 84% in one quarter. Allergy Partners had more than 1,500 patients enrolled across 88% of its clinic locations, and the company counts 40,000 insurance-verified patients on compatible inhalers. Its stated goal is 10,000 RPM device shipments by the end of 2026, nearly triple the March base. The pace was already visible earlier in the year: cumulative shipments rose from 2,149 at 31 December 2025 to 3,071 at 28 February 2026, a 42.9% gain in two months, and the RPM team grew to 58 people from 43.

### Drug compatibility adds 4.3 points

Every new cleared inhaler pairing widens the pool a smart inhaler sensor can serve. Aptar's HeroTracker Sense, the newest FDA-cleared clip-on, fits Ventolin HFA, Advair and certain albuterol and fluticasone/salmeterol inhalers for patients aged 12 and above. Adherium's Hailie sensor is cleared for AstraZeneca's Symbicort pMDI and for GSK's Ellipta inhaler containing fluticasone furoate, umeclidinium and vilanterol. Douglas Insights puts the effect at 4.3 points of yearly device-year growth, because each new pairing opens a prescribing base that already exists. A sensor maker with three cleared pairings can address three brands' prescriptions with one app, one data platform and one clinic contract, so the cost of adding a patient falls as the pairing list grows.

### Disease burden adds 3.5 points

The patient pool is large and poorly controlled. The [World Health Organization (WHO)](https://www.who.int/news-room/fact-sheets/detail/asthma) estimates asthma affected 363 million people in 2023 and caused 442,000 deaths, while COPD caused 3.4 million deaths in 2023. Novartis notes that over 45% of asthma patients at Global Initiative for Asthma (GINA) steps 4 and 5 remain uncontrolled. Those severe patients are where a smart inhaler earns its fee, and they supply 3.5 points of growth. The three contributions, 5.6, 4.3 and 3.5 points, add to the 13.4% volume leg.

## What stands in the way of smart inhaler sensors reaching 363 million asthma patients?

Three restraints remove about 3.5 points from smart inhaler volume growth: clinician time and reimbursement scrutiny take 1.6 points, platform exits and app fatigue take 1.1 points, and patchy inhaler access takes 0.8 points. Without them, device-years would grow near 16.9% a year.

Clinician time removes 1.6 points. Minutes are the bottleneck. A smart inhaler only earns monitoring fees when someone reviews the data: Adherium's ASX sales update lists about US$26 per patient a month for 10 to 19 minutes of management and about US$52 for more than 19 minutes. Small practices without care coordinators struggle to log those minutes for every patient, so many sensors are shipped but never billed.

Platform exits and app fatigue remove 1.1 points. Teva's withdrawal of its Digihaler range left prescribers with stranded patients and made pharma brands wary of building electronics into the inhaler itself. Even in a growing programme, Adherium's 2,622 activations against 3,617 shipments imply that 27.5% of smart inhaler units shipped had not yet been switched on at the latest quarter end.

Access gaps remove 0.8 points. WHO reports that in low- and lower-middle-income countries steroid inhalers were available in fewer than half of public primary health facilities, and bronchodilators in fewer than two-thirds. A smart inhaler sensor has no market where the inhaler itself is missing.

## How much does a smart inhaler programme cost per patient-year, and who pays the monitoring fees?

A smart inhaler device-year averaged USD 231.4 in 2025 across hardware, app and service revenue, and Douglas Insights expects USD 272.5 by 2035 as monitoring fees take a larger share. Realised bands run from under USD 110 for a consumer sensor to above USD 600 in a billed RPM programme.

| Smart inhaler tier | What the buyer gets | Price per device-year | Basis |
| --- | --- | --- | --- |
| Consumer or over-the-counter sensor | Clip-on sensor and app, no clinician review | USD 60 to 110 | Douglas Insights estimate |
| Pharma-bundled companion | Sensor supplied with a branded inhaler | USD 140 to 260 | Douglas Insights estimate |
| Clinic RPM programme | Sensor, platform and monthly clinician review | USD 312 to 624 in management fees alone | US$26 to US$52 a month, ASX update of 10 March 2026 |

The RPM band is simple arithmetic: US$26 a month for 12 months is USD 312, and US$52 a month is USD 624, before any device supply fee. A cross-check from company accounts lands inside it. Adherium booked A$344k of RPM revenue in its latest reported quarter over an average of about 2,024 activated patients, or roughly A$170 per patient per quarter.

Payers fund most of the premium tier. In the US, insurers pay the monthly monitoring codes; in Europe, a smart inhaler is usually funded by the drug maker as a companion. Price per device-year rises only 1.65% a year because hardware gets cheaper while service minutes get dearer. The same payer logic already governs adherence-tracked sleep therapy, covered in our [Continuous Positive Airway Pressure Mask Market](https://www.douglasinsights.com/continuous-positive-airway-pressure-mask-market/).

## Which companies control smart inhaler sensor platforms after Teva's Digihaler exit?

Douglas Insights estimates ResMed's Propeller Health leads with about 21.6% of 2025 smart inhaler value, and the top three platforms, adding Aptar Digital Health and Adherium, hold about 36.2%. No company reports smart inhaler revenue separately, so every share is modelled.

ResMed bought Propeller Health for USD 225 million and runs it inside its respiratory care business, with users in the United States, Europe and Asia. Its position rests on pharma partnerships: Propeller custom-built the sensor in the digital companion for Novartis's Enerzair Breezhaler. Aptar Digital Health builds on Aptar's pharma device business and holds the newest FDA clearance in the category, for HeroTracker Sense. Adherium, the only listed pure play, reports RPM revenue of A$344k a quarter, which is under 1% of the market, but says it has sold more than 180,000 connected respiratory devices.

| Company | Smart inhaler position built on | Disclosed figure |
| --- | --- | --- |
| ResMed (Propeller Health) | Sensor and app platform, pharma companion programmes | USD 225 million purchase price |
| Aptar Digital Health | HeroTracker Sense clip-on for pMDIs | FDA 510(k) Class II clearance, 16 October 2025 |
| Adherium | Hailie sensors and US RPM service | 3,617 cumulative RPM shipments by 31 March 2026 |
| Novartis | Enerzair Breezhaler with digital companion | EC approval, 7 July 2020 |
| AstraZeneca | Symbicort pairing and milestone funding to Adherium | A$264k milestone expected July 2026 |
| GSK | Ellipta inhaler paired with Adherium's Hailie | FDA 510(k) clearance for the Ellipta trio pairing |
| Teva | Former Digihaler built-in range | Three products withdrawn |

AstraZeneca and GSK sit one step back: their brands decide which smart inhaler sensors get cleared, and Adherium expects a further A$264k milestone payment from AstraZeneca in July 2026. Teva shows the downside of building electronics into the inhaler: three products, ProAir, ArmonAir and AirDuo Digihaler, left the market together.

## Where will smart inhaler device-years grow fastest: North America, Europe or Asia Pacific?

North America leads smart inhaler spending with USD 164.8 million in 2025, 51.9% of the total, because US payers fund monthly monitoring codes. Asia Pacific grows fastest, at 20.6% a year, from USD 45.1 million to USD 293.5 million by 2035.

North America reaches USD 627.2 million by 2035 at 14.3% a year; Aptar puts US asthma at 26.8 million people and its economic burden at nearly USD 82 billion a year. Europe holds USD 84.5 million and grows 13.8% a year to USD 307.8 million, led by companion sensors that drug makers fund rather than RPM codes. Asia Pacific starts at USD 45.1 million and is fastest at 20.6%, because large asthma populations meet falling sensor costs and smartphone-led care.

Latin America is the wildcard at USD 13.7 million, growing 15.9% a year to USD 59.9 million if pharma companies extend companion smart inhaler programmes beyond Europe. Middle East and Africa is the smallest region at USD 9.4 million and grows 11.0% a year to USD 26.7 million, held back by the inhaler access gaps WHO records.

## Which inhaler brands can a smart inhaler clip-on read today?

Douglas Insights counts 5 named inhaler families with a cleared or approved smart inhaler sensor in the sources read for this study: Ventolin HFA, Advair, Symbicort, the Ellipta trio and Enerzair Breezhaler. Coverage, not sensor quality, decides how many patients a platform can reach.

HeroTracker Sense records actuation, shake, orientation, coordination and inspiratory strength and duration, but it does not count remaining doses or measure lung function. Adherium's Ellipta-compatible Hailie measures inhalation duration, volume and peak inhalation flow, which turns a dose log into a technique check. Pairings beat features. For a buyer, the practical rule is to match the smart inhaler platform to the two or three inhaler brands that make up most of the clinic's prescriptions.

## Do smart inhaler programmes cut asthma and COPD hospital stays enough to pay back?

Adherium reports a 67% reduction in hospitalisations and average annual savings of US$12,943 per patient from its iCARE study, against USD 312 to USD 624 a year of smart inhaler management fees. On those company figures, savings exceed fees by about 20.7 times.

The same study reports a 57% reduction in hospital length of stay and a 46% reduction in total cost of care. These are company-reported results from one programme, so payers will want independent replication before treating them as a rule. Even at a tenth of the reported saving, USD 1,294 a year still covers the top fee band twice. Broader clinical software that sits beside smart inhaler data is sized in our [Digital Medicine Market](https://www.douglasinsights.com/digital-medicine-market/).

## Which asthma and COPD patients get a smart inhaler first, in clinics or home care?

Douglas Insights estimates specialist allergy and pulmonology clinics enrol 46.2% of 2025 smart inhaler device-years, hospitals 18.5% and home care 35.3%. Specialists move first because they treat severe asthma and own the monitoring code workflow, while home care rises with over-the-counter sensors.

Clinic networks show the pattern. Adherium reports SENTA Partners active across 95% of its clinics with about 27,000 eligible patients, six live locations at CIIC, and 10 new independent practices with about 18,000 eligible patients. Hospitals use smart inhaler data at discharge, when a patient is most likely to be readmitted. Home care grows as over-the-counter sensors reach patients without a specialist.

## Which rules govern smart inhaler sensors, from FDA 510(k) clearance to the EU F-gas quota?

Smart inhaler sensors sold in the US are regulated as medical devices: HeroTracker Sense was cleared as a Class II device through the 510(k) route. In the European Union (EU), Regulation (EU) 2024/573 puts pMDI propellants into the hydrofluorocarbon (HFC) quota, with full reduction from 2030.

The [EU F-gas Regulation](https://eur-lex.europa.eu/eli/reg/2024/573/oj) was adopted on 7 February 2024 and entered into force on 11 March 2024. It gives the metered dose inhaler sector its full quota for 2025 and 2026 and applies the full reduction rate only in 2030. The consequence for smart inhaler makers is engineering work: reformulated pMDIs with new propellants bring new canisters and actuators, and a clip-on sensor cleared for one geometry must be re-validated for the next. Douglas Insights expects that redesign cycle to favour sensor makers that already hold several pairings.

Companion sensors follow the drug. The European Commission (EC) approved Enerzair Breezhaler with its optional digital companion on [7 July 2020](https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-enerzair-breezhaler-including-first-digital-companion-sensor-and-app-can-be-prescribed-alongside-treatment-uncontrolled-asthma-eu), valid in all 27 EU member states plus the UK, Iceland, Norway and Liechtenstein, 31 countries in total. In the US, the money depends on Current Procedural Terminology (CPT) monitoring codes such as 99470 and 99457, which Adherium cites at about US$26 and US$52 a month.

## Smart inhaler forecast to 2035: what if RPM billing stalls, or pharma bundles a sensor with every pMDI?

In the base case smart inhaler revenue reaches USD 1.32 billion in 2035. A slower case lands at USD 893.3 million, a 10.90% CAGR, and a faster case at USD 1.88 billion, a 19.47% CAGR. The USD 987.7 million gap between the outer cases shows how much rides on payer behaviour.

The slower case runs volume at 9.8% and price at 1.0%: payers tighten monitoring codes, more clinics stall below the billing minutes and another pharma brand withdraws a connected inhaler, as Teva did. The faster case runs volume at 16.9% and price at 2.2%: the three restraints fade, pairings like the HeroTracker Sense clearance multiply during the propellant switch, and RPM programmes hit targets such as Adherium's 10,000 shipments.

One extra point of yearly device-year growth adds about USD 120.7 million to the 2035 smart inhaler total; one point less takes away about USD 111.5 million. Outside forecasts we read span 12.95% to 19.6% a year, and several of them count drug value; our 15.27% sits in the lower half because we exclude the medicine.

## Douglas Exclusive: the Smart Inhaler Platform Evidence Scorecard

The Smart Inhaler Platform Evidence Scorecard is a Douglas Insights model built from 25 sourced data points in 8 primary documents. It scores five smart inhaler platforms from 0 to 5 on four tests, for a maximum of 20: documented regulatory status, named drug pairings, disclosed scale and a disclosed payment route.

| Platform | Regulatory status | Drug pairings | Disclosed scale | Payment route | Score out of 20 |
| --- | --- | --- | --- | --- | --- |
| Adherium Hailie | 5 | 5 | 4 | 5 | 19 |
| Aptar HeroTracker Sense | 5 | 4 | 1 | 1 | 11 |
| Novartis Enerzair digital companion | 5 | 2 | 2 | 1 | 10 |
| ResMed Propeller Health | 3 | 3 | 2 | 1 | 9 |
| Teva Digihaler | 4 | 3 | 0 | 0 | 7 |

The scorecard counts evidence a buyer can check, not market share. Scores are our judgment against the sourced facts: a 5 means a dated clearance or approval, two or more named pairings, a shipment or patient count, or a priced billing route. The finding is a gap of 12 points between the best and worst platforms. Only one smart inhaler platform, with 19 of 20, discloses both patient counts and a billing route; the share leader scores 9 because its scale is not published.

## Smart inhaler methodology: which receipts turn 363 million asthma patients into 1.372 million device-years?

Our model applies a 0.378% connected-device ratio to WHO's 363 million asthma patients, giving 1.372 million smart inhaler device-years in 2025. Multiplied by USD 231.4, that is USD 317.5 million; COPD users are folded into the same ratio, and no drug value enters the receipt.

The model covers 5 regions and 4 product segments, and uses 25 sourced data points. Volume then grows 13.4% a year to 4.825 million device-years in 2035, at USD 272.5 each, giving USD 1.32 billion. Regional values sum exactly to the global total in 2025 and 2035; segment values sum exactly in 2025 and to within 0.05% in 2035. The 2026 value is USD 366.0 million.

Three cross-checks were run. Adherium's A$170 per activated patient per quarter, about A$680 a year, lands in the same range as our RPM tier. The one device-only outside estimate for 2025 we read is 14.0% above ours, which we attribute to a wider product scope. Our 15.27% CAGR falls 1.01 points below the 16.28% midpoint of the published range, consistent with excluding drug value.

## Market by segment

| Segment | Share | Value |
| --- | --- | --- |
| Add-on sensors for pressurised metered dose inhalers | 38.7% | $122.8 Mn |
| Add-on sensors for dry powder inhalers | 17.6% | $55.9 Mn |
| Integrated connected inhalers | 16.3% | $51.8 Mn |
| Remote monitoring and adherence services | 27.4% | $87.0 Mn |

## Market by region (USD million)

| Region | 2025 | 2026 | 2035 | CAGR 2026-2035 |
| --- | --- | --- | --- | --- |
| Global | 317.5 | 366 | 1,315.1 | 15.27% |
| North America | 164.8 | 188.4 | 627.2 | 14.3% |
| Europe | 84.5 | 96.2 | 307.8 | 13.8% |
| Asia Pacific | 45.1 | 54.4 | 293.5 | 20.6% |
| Latin America | 13.7 | 15.9 | 59.9 | 15.9% |
| Middle East and Africa | 9.4 | 10.4 | 26.7 | 11% |

## Dataset

| Series | Value | Unit |
| --- | --- | --- |
| Market size 2025 | 317.5 | USD million |
| Market size 2035 | 1,315.1 | USD million |
| Revenue CAGR 2026-2035 | 15.27 | percent |
| Volume CAGR 2026-2035 | 13.4 | percent |
| Price per device-year CAGR 2026-2035 | 1.65 | percent |

## Frequently asked questions

### How is the smart inhaler revenue figure for 2025 built?

1.372 million device-years in use multiplied by a blended USD 231.4 per device-year gives USD 317.5 million in 2025. The drug inside the inhaler is excluded.

### What will smart inhalers be worth by 2035 in the base case?

USD 1.32 billion in 2035, a 15.27% CAGR built from 13.4% volume growth and 1.65% price growth. The slower case is USD 893.3 million and the faster case USD 1.88 billion.

### Which smart inhaler product earns the most revenue?

38.7% of 2025 value, USD 122.8 million, goes to add-on sensors for pressurised metered dose inhalers, because one clip-on fits many canister brands.

### Why do monitoring services outpace sensor hardware?

19.3% a year is the growth rate of remote monitoring and adherence services, from USD 87.0 million in 2025, because clinics bill monthly for reviewing inhaler data.

### What does a clinic RPM programme with a smart inhaler cost per year?

USD 312 to USD 624 a year in management fees alone, based on about US$26 to US$52 per patient a month cited in Adherium's ASX update.

### Who leads the smart inhaler platform business?

21.6% of 2025 value sits with ResMed's Propeller Health, Douglas Insights estimates, and the top three platforms hold about 36.2%.

### Where is smart inhaler spending largest and where is it rising quickest?

51.9% of 2025 spending, USD 164.8 million, is in North America. Asia Pacific grows quickest at 20.6% a year to USD 293.5 million by 2035.

### How does the EU F-gas Regulation affect smart inhaler sensors?

2030 is when the metered dose inhaler sector meets the full HFC reduction rate under Regulation (EU) 2024/573, so new propellants and canisters force clip-on sensors to be re-validated.

## Sources

- [Adherium Limited, ASX, Adherium Hailie Smartinhaler quarter-to-date sales update](https://announcements.asx.com.au/asxpdf/20260310/pdf/06x7w6273qyj2t.pdf)
- [Adherium Limited, ASX, Appendix 4C quarterly report to 31 March 2026](https://announcements.asx.com.au/asxpdf/20260429/pdf/06yzsssz90rd8p.pdf)
- [AptarGroup, Aptar Digital Health announces FDA 510(k) clearance for HeroTracker Sense](https://aptar.com/news-events/aptar-digital-health-announces-fda-510-k-clearance-for-herotracker-sense)
- [Novartis, Novartis receives EC approval for Enerzair Breezhaler including first digital companion](https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-enerzair-breezhaler-including-first-digital-companion-sensor-and-app-can-be-prescribed-alongside-treatment-uncontrolled-asthma-eu)
- [World Health Organization, Asthma fact sheet](https://www.who.int/news-room/fact-sheets/detail/asthma)
- [EUR-Lex, Regulation (EU) 2024/573 on fluorinated greenhouse gases](https://eur-lex.europa.eu/eli/reg/2024/573/oj)
- [ResMed, ResMed completes USD 225 million acquisition of Propeller Health](https://investor.resmed.com/news-events/press-releases/detail/132/resmed-completes-225-million-acquisition-of-propeller-health)

## How to cite

Douglas Insights, "Smart Inhalers Market", DI-HC-10475, updated 2026-10-05, https://www.douglasinsights.com/smart-inhalers-market/